| 2016-11-30 14:16:46|
ALKS 14:16 11/30 11/30/16
USPTO institutes inter partes review of Alkermes '061 patent
The U.S. Patent and Trademark Office's Patent Trial and Appeal Board determined that Luye Pharma Group has demonstrated a reasonable likelihood that it would prevail in showing the unpatentability of claims 1-13 and 17-23 of U.S. Patent No. 6,667,061 held by Alkermes. Accordingly, the PTAB has instituted a requested inter partes review of those claims. The '061 patent is an Orange Book-listed patent for each of Bydureon, Risperdal Consta and Vivitrol.